A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ACE-031 (ActRIIB-IgG1) in Healthy, Postmenopausal Volunteers
Latest Information Update: 24 May 2023
At a glance
- Drugs Ramatercept (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Acceleron Pharma
Most Recent Events
- 16 May 2014 New trial record